Diagnostic cardiac catheterizations are predominantly
performed using the femoral
artery access. Several devices have been
developed to aid in the closure of femoral arteriotomy.
Safeguard® is a new pneumatic compression device that has been developed for compression of the femoral artery after brief manual compression. We hereby report the case of an elderly patient who underwent a percutaneous coronary intervention via the femoral artery in whom a Safeguard™ device, left overnight because of persistent oozing, provoked an extensive pressure ulcer. Knowledge of this potential complication is important to minimize its occurance and provide appropriate treatment.
Cardiac catheterization, closure vascular access, femoral closure device, vascular access complication.
Claudio Moretti, Division of Cardiology, University of Turin, San Giovanni Battista “Molinette” Hospital, Corso Bramante 88–90, 10126 Turin, Italy. Tel. +39.011.6334195 – Fax: +39.011.6967053. E-mail: firstname.lastname@example.org
Share this Article
Related Content In Interventional Cardiology
Management of Atrial Fibrillation in Recipients of Cardiac Resynchronization Therapy
European Journal of Arrhythmia & Electrophysiology. 2021;7(1):19-25 DOI: https://doi.org/10.17925/EJAE.2021.7.1.19
Atrial fibrillation (AF) and heart failure (HF) often co-exist. The incidence of AF is estimated to reach 45% of patients with HF and rises with the severity of HF symptoms, from about 5% of patients in the New York Heart Association (NYHA) class I to 50% in NYHA class IV.1–4 Consistently, the incidence of AF […]
The ACURATE neo™ and neo2™ Valve Systems
Heart International. 2021;15(1):37-41 DOI: https://doi.org/10.17925/HI.2021.15.1.37
Transcatheter aortic valve replacement (TAVR) has seen worldwide explosive growth. The current USA guidelines no longer use risk in choosing between TAVR and surgical aortic valve replacement, and the European guidelines have extended the recommendation for TAVR to lower risk groups.1,2 This rapid expansion has been driven by data from randomized trials showing TAVR as […]
Foreword – Heart International. 2020;14(2):66
Welcome to the latest edition of Heart International. I would like to begin by paying tribute to all the victims of the coronavirus pandemic. I know of very few people who have not lost a family member, friend, colleague or a neighbour with COVID-19. Such deaths are not simply statistics, for behind each death is a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!